<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03408171</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0391</org_study_id>
    <nct_id>NCT03408171</nct_id>
  </id_info>
  <brief_title>Comparison of 19g FNA and 19g FNB Needles for EUS-LB</brief_title>
  <official_title>19-Gauge Fine Needle Aspirate (FNA) Versus 19-Gauge Fine Needle Biopsy (FNB) Needles for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geisinger Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic liver disorders (CLD) are a major cause of morbidity and mortality for individuals in
      the US. Though serologic analysis will often lead to a conclusive diagnosis, liver biopsy
      remains an important method for helping to determine the etiology and stage of LD.
      Percutaneous liver biopsy (PLB), transjugular liver biopsy (TLB) and surgical liver biopsy
      (SLB) are alternative methods for obtaining hepatic tissue. In recent years endoscopic
      ultrasound guided-liver biopsy (EUS-LB) has come to the forefront as a safe and effective
      method for obtaining tissue in CLD. There are several studies of the safety of EUS-LB as well
      as the adequacy of specimens obtained in this fashion. Most studies involve a 19-g needle,
      therefore in this study we hope to compare the tissue yields of a 19-g FNB needle, in
      comparison to conventional 19-g FNA needle. We predict that 19-g FNA and 19-g FNB needle will
      demonstrate similar diagnostic accuracy, with less visible blood artifact. Similarly, we
      predict the safety to be equal.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two groups for the duration of the study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specimen quality for histologic diagnosis</measure>
    <time_frame>3-5 days</time_frame>
    <description>Proportion of cases for which a histologic diagnosis could be made based upon the amount of tissue obtained with the needle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Portal tract quantity</measure>
    <time_frame>3-5 days</time_frame>
    <description>Number of portal tracts (PT) in the specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specimen length</measure>
    <time_frame>3-5 days</time_frame>
    <description>Aggregate specimen length (ASL) &amp; length of the longest piece (LLP) measured in millimeters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs and SAEs</measure>
    <time_frame>1 week</time_frame>
    <description>Adverse events (AE) and serious adverse events (SAE).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Abnormal Liver Function</condition>
  <arm_group>
    <arm_group_label>19-gauge FNA needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>19-gauge FNB needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>19-gauge FNA needle</intervention_name>
    <description>A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.</description>
    <arm_group_label>19-gauge FNA needle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>19-gauge FNB needle</intervention_name>
    <description>A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.</description>
    <arm_group_label>19-gauge FNB needle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing EUS-LB

          2. Platelet count &gt; 50,000

          3. International normalized ratio (INR) &lt; 1.5

          4. Age &gt; 18 years

          5. Non-pregnant patients

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Pregnant patients

          3. Inability to obtain consent

          4. Anticoagulants or anti-platelet agents use (excluding aspirin) within the last 7-10
             days

          5. Platelet count &lt; 50,000

          6. INR &gt; 1.5

          7. Presence of ascites

          8. Known liver cirrhosis

          9. Hemophilia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Diehl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geisinger Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan E LaMotte</last_name>
    <phone>5702142411</phone>
    <email>melamotte@geisinger.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jamie Seiler</last_name>
    <phone>5702142740</phone>
    <email>jlseiler@geisinger.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan E LaMotte</last_name>
      <phone>570-214-2411</phone>
      <email>melamotte@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jamie Seiler</last_name>
      <phone>570-214-2740</phone>
      <email>jlseiler@geisinger.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD; American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009 Mar;49(3):1017-44. doi: 10.1002/hep.22742.</citation>
    <PMID>19243014</PMID>
  </reference>
  <reference>
    <citation>Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology. 2006 Feb;43(2 Suppl 1):S113-20. Review.</citation>
    <PMID>16447288</PMID>
  </reference>
  <reference>
    <citation>Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005 Jan;41(1):48-54.</citation>
    <PMID>15690481</PMID>
  </reference>
  <reference>
    <citation>Sherlock S, Dick R, Van Leeuwen DJ. Liver biopsy today. The Royal Free Hospital experience. J Hepatol. 1985;1(1):75-85. Review.</citation>
    <PMID>3902951</PMID>
  </reference>
  <reference>
    <citation>Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaitini D, Baruch Y. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg. 2003 May;96(5):1392-6, table of contents.</citation>
    <PMID>12707140</PMID>
  </reference>
  <reference>
    <citation>Firpi RJ, Soldevila-Pico C, Abdelmalek MF, Morelli G, Judah J, Nelson DR. Short recovery time after percutaneous liver biopsy: should we change our current practices? Clin Gastroenterol Hepatol. 2005 Sep;3(9):926-9.</citation>
    <PMID>16234032</PMID>
  </reference>
  <reference>
    <citation>Stone MA, Mayberry JF. An audit of ultrasound guided liver biopsies: a need for evidence-based practice. Hepatogastroenterology. 1996 Mar-Apr;43(8):432-4.</citation>
    <PMID>8714240</PMID>
  </reference>
  <reference>
    <citation>McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990 Nov;99(5):1396-400.</citation>
    <PMID>2101588</PMID>
  </reference>
  <reference>
    <citation>Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993 Jan 15;118(2):96-8.</citation>
    <PMID>8416324</PMID>
  </reference>
  <reference>
    <citation>Huang JF, Hsieh MY, Dai CY, Hou NJ, Lee LP, Lin ZY, Chen SC, Wang LY, Hsieh MY, Chang WY, Yu ML, Chuang WL. The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies. Gut. 2007 May;56(5):736-7.</citation>
    <PMID>17440193</PMID>
  </reference>
  <reference>
    <citation>Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001 Feb 15;344(7):495-500. Review.</citation>
    <PMID>11172192</PMID>
  </reference>
  <reference>
    <citation>Bull HJ, Gilmore IT, Bradley RD, Marigold JH, Thompson RP. Experience with transjugular liver biopsy. Gut. 1983 Nov;24(11):1057-60.</citation>
    <PMID>6629116</PMID>
  </reference>
  <reference>
    <citation>Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc. 1996 Jun;43(6):568-71.</citation>
    <PMID>8781934</PMID>
  </reference>
  <reference>
    <citation>Denzer U, Arnoldy A, Kanzler S, Galle PR, Dienes HP, Lohse AW. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol. 2007 Jan;41(1):103-10.</citation>
    <PMID>17198072</PMID>
  </reference>
  <reference>
    <citation>Diehl DL, Johal AS, Khara HS, Stavropoulos SN, Al-Haddad M, Ramesh J, Varadarajulu S, Aslanian H, Gordon SR, Shieh FK, Pineda-Bonilla JJ, Dunkelberger T, Gondim DD, Chen EZ. Endoscopic ultrasound-guided liver biopsy: a multicenter experience. Endosc Int Open. 2015 Jun;3(3):E210-5. doi: 10.1055/s-0034-1391412. Epub 2015 Feb 27.</citation>
    <PMID>26171433</PMID>
  </reference>
  <reference>
    <citation>DeWitt J, LeBlanc J, McHenry L, Ciaccia D, Imperiale T, Chappo J, Cramer H, McGreevy K, Chriswell M, Sherman S. Endoscopic ultrasound-guided fine needle aspiration cytology of solid liver lesions: a large single-center experience. Am J Gastroenterol. 2003 Sep;98(9):1976-81.</citation>
    <PMID>14499774</PMID>
  </reference>
  <reference>
    <citation>tenBerge J, Hoffman BJ, Hawes RH, Van Enckevort C, Giovannini M, Erickson RA, Catalano MF, Fogel R, Mallery S, Faigel DO, Ferrari AP, Waxman I, Palazzo L, Ben-Menachem T, Jowell PS, McGrath KM, Kowalski TE, Nguyen CC, Wassef WY, Yamao K, Chak A, Greenwald BD, Woodward TA, Vilmann P, Sabbagh L, Wallace MB. EUS-guided fine needle aspiration of the liver: indications, yield, and safety based on an international survey of 167 cases. Gastrointest Endosc. 2002 Jun;55(7):859-62.</citation>
    <PMID>12024141</PMID>
  </reference>
  <reference>
    <citation>Sey MS, Al-Haddad M, Imperiale TF, McGreevy K, Lin J, DeWitt JM. EUS-guided liver biopsy for parenchymal disease: a comparison of diagnostic yield between two core biopsy needles. Gastrointest Endosc. 2016 Feb;83(2):347-52. doi: 10.1016/j.gie.2015.08.012. Epub 2015 Aug 13.</citation>
    <PMID>26278654</PMID>
  </reference>
  <reference>
    <citation>Dewitt J, McGreevy K, Cummings O, Sherman S, Leblanc JK, McHenry L, Al-Haddad M, Chalasani N. Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc. 2009 Mar;69(3 Pt 1):535-42. doi: 10.1016/j.gie.2008.09.056.</citation>
    <PMID>19231495</PMID>
  </reference>
  <reference>
    <citation>Gor N, Salem SB, Jakate S, Patel R, Shah N, Patil A. Histological adequacy of EUS-guided liver biopsy when using a 19-gauge non-Tru-Cut FNA needle. Gastrointest Endosc. 2014 Jan;79(1):170-2. doi: 10.1016/j.gie.2013.06.031. Epub 2013 Jul 31.</citation>
    <PMID>23916397</PMID>
  </reference>
  <reference>
    <citation>Stavropoulos SN, Im GY, Jlayer Z, Harris MD, Pitea TC, Turi GK, Malet PF, Friedel DM, Grendell JH. High yield of same-session EUS-guided liver biopsy by 19-gauge FNA needle in patients undergoing EUS to exclude biliary obstruction. Gastrointest Endosc. 2012 Feb;75(2):310-8. doi: 10.1016/j.gie.2011.09.043.</citation>
    <PMID>22248599</PMID>
  </reference>
  <reference>
    <citation>Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003 Aug;39(2):239-44.</citation>
    <PMID>12873821</PMID>
  </reference>
  <reference>
    <citation>Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology. 1998 Aug;28(2):323-31.</citation>
    <PMID>9695993</PMID>
  </reference>
  <reference>
    <citation>Röcken C, Meier H, Klauck S, Wolff S, Malfertheiner P, Roessner A. Large-needle biopsy versus thin-needle biopsy in diagnostic pathology of liver diseases. Liver. 2001 Dec;21(6):391-7.</citation>
    <PMID>11903883</PMID>
  </reference>
  <reference>
    <citation>Bhatia V, Hijioka S, Hara K, Mizuno N, Imaoka H, Yamao K. Endoscopic ultrasound description of liver segmentation and anatomy. Dig Endosc. 2014 May;26(3):482-90. doi: 10.1111/den.12216. Epub 2013 Dec 19.</citation>
    <PMID>24355092</PMID>
  </reference>
  <reference>
    <citation>ASGE Standards of Practice Committee, Early DS, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Hwang JH, Jue TL, Khashab MA, Lightdale JR, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf RN, Shergill AK, Cash BD. Adverse events associated with EUS and EUS with FNA. Gastrointest Endosc. 2013 Jun;77(6):839-43. doi: 10.1016/j.gie.2013.02.018.</citation>
    <PMID>23684089</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027.</citation>
    <PMID>20189503</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver biopsy</keyword>
  <keyword>endoscopic ultrasound guided liver biopsy</keyword>
  <keyword>FNA</keyword>
  <keyword>FNB</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

